A combination of myokines and genistein suppresses cancer stemness in MCF-7 human breast cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyeji Kwon | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | Jung-Hyun Kim | - |
dc.date.accessioned | 2024-06-25T05:30:44Z | - |
dc.date.available | 2024-06-25T05:30:44Z | - |
dc.date.issued | 2024-06 | - |
dc.identifier.issn | 1976-1457 | - |
dc.identifier.issn | 2005-6168 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74383 | - |
dc.description.abstract | BACKGROUND/OBJECTIVES: Breast cancer is considered a serious health issue worldwide and is influenced by risk factors, including physical inactivity and unhealthy diet. Myokines secreted by muscles during physical activity play a crucial role in cancer development and the immune system. Genistein (Gen), an isoflavone primarily in legumes, induces anti-cancer activity by regulating cancer stem cells (CSCs). Therefore, this study investigated the potential anti-cancer effect of a combination of myokine and Gen on the human breast cancer MCF-7 cells. MATERIALS/METHODS: MCF-7, a human breast cancer cell line, was used for in vitro study. The cell viability of MCF-7 cells was evaluated in response to treatment with myokines, irisin (Iri), oncostatin M (OSM), and Gen using the MTT assay. Clonogenic and sphere formation assays were used to evaluate the self-renewal capacity of breast CSCs. The mRNA expression levels of stem cell markers were analyzed in MCF-7 breast cancer cells. RESULTS: Administering Iri or OSM with Gen significantly inhibited the self-renewal capacity of MCF-7 cells. In addition, mRNA expression of breast CSC markers SOX2 and OCT4, which are characteristic of CSCs, was suppressed by both myokine and Gen. However, combining Iri or OSM with Gen was the most effective treatment. CONCLUSION: These results suggested that combining Iri or OSM with Gen has an additive effect on breast CSCs by regulating self-renewal capacity and expression of CSCs markers. Therefore, the combination of myokines and Gen may have the therapeutic potential for treating breast cancer and improving the quality of life of cancer patients. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국영양학회 | - |
dc.title | A combination of myokines and genistein suppresses cancer stemness in MCF-7 human breast cancer cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.4162/nrp.2024.18.3.436 | - |
dc.identifier.bibliographicCitation | Nutrition Research and Practice, v.18, no.3, pp 436 - 445 | - |
dc.identifier.kciid | ART003085887 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001242971000010 | - |
dc.identifier.scopusid | 2-s2.0-85196652645 | - |
dc.citation.endPage | 445 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 436 | - |
dc.citation.title | Nutrition Research and Practice | - |
dc.citation.volume | 18 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | cancer stem cells | - |
dc.subject.keywordAuthor | genistein | - |
dc.subject.keywordAuthor | myokines | - |
dc.subject.keywordPlus | EXERCISE | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.relation.journalResearchArea | Nutrition & Dietetics | - |
dc.relation.journalWebOfScienceCategory | Nutrition & Dietetics | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.